| Homelessness and Social Issues | Lifetime | 2 | IE 1 | 99.95 |
| Cannabis and Cannabinoid Research | Lifetime | 3 | IE 1 | 99.91 |
| Opioid Use Disorder Treatment | Lifetime | 2 | IE 1 | 99.92 |
| Prenatal Substance Exposure Effects | Lifetime | 2 | IE 1 | 99.90 |
| Substance Abuse Treatment and Outcomes | Lifetime | 4 | IE 1 | 99.93 |
| HIV, Drug Use, Sexual Risk | Lifetime | 20 | IE 1 | 99.77 |
| Forensic Toxicology and Drug Analysis | Lifetime | 10 | IE 1 | 99.54 |
| Alcohol Consumption and Health Effects | Lifetime | 27 | IE 1 | 99.53 |
| Smoking Behavior and Cessation | Lifetime | 26 | IE 1 | 99.36 |
| Psychedelics and Drug Studies | Lifetime | 21 | IE 1 | 98.81 |
| Blood Pressure and Hypertension Studies | Lifetime | 347 | IE 4 | 98.91 |
| Neuroethics, Human Enhancement, Biomedical Innovations | Lifetime | 18 | IE 1 | 98.07 |
| Global Public Health Policies and Epidemiology | Lifetime | 164 | IE 1 | 97.84 |
| Bipolar Disorder and Treatment | Lifetime | 232 | IE 1 | 98.60 |
| Mental Health Treatment and Access | Lifetime | 309 | IE 1 | 98.52 |
| Poisoning and overdose treatments | Lifetime | 116 | IE 3 | 97.50 |
| Schizophrenia research and treatment | Lifetime | 443 | IE 2 | 98.49 |
| Pain Management and Opioid Use | Lifetime | 189 | IE 2 | 97.88 |
| Health disparities and outcomes | Lifetime | 616 | IE 2 | 97.69 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 415 | IE 1 | 97.27 |
| Healthcare Decision-Making and Restraints | Lifetime | 264 | IE 2 | 95.05 |
| Nicotinic Acetylcholine Receptors Study | Lifetime | 672 | IE 5 | 95.30 |
| Suicide and Self-Harm Studies | Lifetime | 677 | IE 6 | 95.27 |
| Alcoholism and Thiamine Deficiency | Lifetime | 275 | IE 2 | 93.80 |
| Treatment of Major Depression | Lifetime | 733 | IE 3 | 95.17 |
| Nutrition, Genetics, and Disease | Lifetime | 785 | IE 10 | 92.42 |
| Gambling Behavior and Treatments | Lifetime | 298 | IE 3 | 91.84 |
| Sodium Intake and Health | Lifetime | 616 | IE 4 | 91.68 |
| Public Health Policies and Education | Lifetime | 498 | IE 3 | 88.67 |
| Consumer Attitudes and Food Labeling | Lifetime | 946 | IE 16 | 89.92 |
| School Health and Nursing Education | Lifetime | 965 | IE 9 | 87.97 |
| Pharmaceutical industry and healthcare | Lifetime | 511 | IE 1 | 86.93 |
| Doping in Sports | Lifetime | 807 | IE 8 | 61.04 |
| Census and Population Estimation | Lifetime | 936 | IE 4 | 47.20 |
| Cannabis and Cannabinoid Research | 2021-2025 | 1 | IE 1 | 99.75 |
| Prenatal Substance Exposure Effects | 2021-2025 | 4 | IE 1 | 99.38 |
| Substance Abuse Treatment and Outcomes | 2021-2025 | 8 | IE 1 | 99.45 |
| Smoking Behavior and Cessation | 2021-2025 | 14 | IE 1 | 98.87 |
| Forensic Toxicology and Drug Analysis | 2021-2025 | 16 | IE 1 | 97.42 |
| Chemical synthesis and alkaloids | 2021-2025 | 40 | IE 1 | 96.30 |
| Neurotransmitter Receptor Influence on Behavior | 2021-2025 | 81 | IE 1 | 95.30 |
| Homelessness and Social Issues | 2021-2025 | 141 | IE 1 | 94.72 |
| Obesity, Physical Activity, Diet | 2021-2025 | 470 | IE 2 | 95.40 |
| Psychedelics and Drug Studies | 2021-2025 | 45 | IE 1 | 96.32 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 147 | IE 1 | 92.33 |
| Nicotinic Acetylcholine Receptors Study | 2021-2025 | 160 | IE 1 | 83.30 |
| Opioid Use Disorder Treatment | 2021-2025 | 791 | IE 3 | 85.37 |
| Alcohol Consumption and Health Effects | 2021-2025 | 896 | IE 2 | 76.52 |
| Consumer Attitudes and Food Labeling | 2021-2025 | 941 | IE 9 | 73.14 |
| Advanced Causal Inference Techniques | 2021-2025 | 621 | IE 2 | 65.04 |
